



PTO/SB/08 Equivalent

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)  SHEET 1 OF 1	Application No.	10/665,203
	Filing Date	September 18, 2003
	First Named Inventor	Wen, et al.
	Art Unit	1618
	Examiner	Fay, Zohreh A
	Attorney Docket No.	MACUS.002A

### U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
Z.F.	1	5,530,006	06-25-1996	Waranis, et al	
	2	5,559,121	09-24-1996	Harrison, et al.	
	3	5,616,588	04-01-1997	Waranis, et al	
	4	5,883,082	03-16-1999	Bennett, et al.	
	5	2003/0018044 A1	01-23-2003	Peyman	
Z.F.	6	2003/0069560 A1	04-10-2003	Adamis et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
Z.F.	7	WO 2004/074445 A2	09-30-2004	COLD SPRING HARBOR LABORATORY, et al.		
	8	WO 00/40089 A1	07-13-2000	Massachusetts Eye and Ear Infirmary		
	9	WO 02/74196 A1	09-26-2002	The United States of America, represented by The Secretary, Department of Health and Human Services		
Z.F.	10	WO 2004/027027 A2	04-01-2004	University of Pennsylvania		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
Z.F.	11	Hackstein et al., "Rapamycin inhibits macropinocytosis and mannose receptor-mediated...", <i>Blood</i> ; Vol. 100 No. 3 (1084-1087), August 2002.	
	12	Rivera et al., "Long-term regulated expression of growth hormone in mice after intramuscular gene transfer," <i>PNAS</i> ; Vol. 96: 8657-8662, July 1999.	
	13	Simamora, P. et al., "Solubilization of Rapamycin," <i>Int. J. Pharm.</i> 213:25-29, February 1, 2001.	
Z.F.	14	Stepkowski et al., "Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat," <i>Transplantation</i> , Vol. 51:22-26, Jan. 1991.	

2973910:sad  
092906

Examiner Signature <i>Zohreh Fay</i>	Date Considered <i>6/23/07</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 4

Application No.

10/665,203

Filing Date

September 18, 2003

First Named Inventor

Rong Wen

Art Unit

1618

Examiner

Zohreh A. Fay

Attorney Docket No.

MACUS.002A

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
2 F	1	2003-0027744	02-06-2003	M. Dana	
	2	2004-0092435	05-13-2004	Peyman	
	3	5,011,844	04-30-1991	Fehr	
	4	5,100,899	03-31-1992	Calne	
	5	5,189,042	02-23-1993	Goulet, et al.	
	6	5,192,773	03-09-1993	Armistead	
	7	5,258,389	11-02-1993	Goulet, et al.	
	8	5,368,865	11-29-1994	Asakura, et al.	
	9	5,378,475	01-03-1995	Smith, et al.	
	10	5,387,589	02-07-1995	Kulkarni	
	11	5,457,111	10-10-1995	Luly, et al.	
	12	5,514,686	05-07-1996	Mochizuki	
	13	5,527,907	06-18-1996	Or, et al.	
	14	5,532,248	07-02-1996	Goulet, et al.	
	15	5,621,108	04-15-1997	Smith, III et al.	
	16	5,672,605	09-30-1997	Or, et al.	
	17	5,773,019	06-30-1998	Ashton, et al.	
	18	6,015,815	01-18-2000	Mollison	
	19	6,329,386	12-11-2002	Mollison	
	20	6,376,517	04-23-2002	Ross, et al.	
	21	6,399,629 B1	06-04-2002	Chamberland et al.	
	22	6,440,990	08-27-2002	Cottens, et al.	
	23	6,534,693	03-18-2003	Fischell, et al.	
	24	6,576,224	06-10-2003	Osbakken et al.	
	25	6,632,836	10-14-2003	Baker, et al.	
	26	6,699,493	03-02-2004	Wong	
	27	6,713,081	03-30-2004	Robinson et al	
	28	6,812,220	11-02-2004	Jackson, et al.	
2 F	29	6,872,383	03-29-2005	Ueno	

Examiner Signature

Zohreh A. Fay

Date Considered

6/23/07

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>	Application No.	10/665,203	
	Filing Date	September 18, 2003	
	First Named Inventor	Rong Wen	
	Art Unit	1618	
(Multiple sheets used when necessary)		Examiner	Zohreh A. Fay
SHEET 2 OF 4		Attorney Docket No.	MACUS.002A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	30	6,890,546	09-05-2002	Mollison, et al.	
ZF	31	US 2003/0031631	02-13-2003	Osbakken et al.	
	32	US 2003/0077297	04-24-2003	Chen et al.	
	33	US 2003/0190286	10-09-2003	Dugger et al.	
	34	US 2004/0018228	01-29-2004	Fischell et al.	
	35	US 2004/0057958	03-25-2004	Waggoner et al.	
	36	US 2004/0234611	11-25-2004	Ahlheim et al.	
	37	US 2005/0025810	02-03-2005	Peyman	
	38	US 2005/0048123	03-03-2005	Su et al.	
	39	US 2005/0123605	06-09-2005	Hunter et al.	
ZF	40	US 60/503,840		Cooper et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
ZF	41	EP 0041795 B1	01-16-1985	Ayerst, McKenna And Harrison Inc.		
	42	WO 1993/19763	10-14-1993	American Home Products		
	43	WO 1999/20261	04-29-1999	Ponikau et al.		
	44	WO 1999/22722	05-14-1999	Abbott Laboratories		
	45	WO 1999/034830	05-17-1999	Galena		
	46	WO 99/37667	07-29-1999	MICROCIDE Pharmaceuticals, INC.		
	47	WO 2000/028945	05-25-2000	Ortho-McNeil Pharmaceutical, Inc.		
	48	WO 2001/47495	07-05-2001	Pfizer Products Inc.		
	49	WO 2002/028387	04-11-2002	Oncopharmaceutical, Inc.		
	50	WO 2002/062335	08-15-2002	Vascular Therapies, llc		
	51	WO 2003/068186	08-21-2003	Lipocine, Inc.		
	52	WO 2003/074027	09-12-2003	Novagali Pharma SA		
ZF	53	WO 2003/074029	09-12-2003	Vectura Limited		

Examiner Signature	<i>Zohreh A. Fay</i>	Date Considered	6/23/07
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/665,203
	Filing Date	September 18, 2003
	First Named Inventor	Rong Wen
	Art Unit	1618
(Multiple sheets used when necessary)	Examiner	Zohreh A. Fay
SHEET 3 OF 4	Attorney Docket No.	MACUS.002A

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
2F	54	WO 2003/090684	11-06-2003	Sun Bow Co., Ltd.		
	55	WO 2004/019904	03-11-2004	Novadel Pharma Inc.		
	56	WO 2004/028477	04-08-2004	Innorr, Inc.		
	57	WO 2004/043480	05-27-2004	Peyman		
2F	58	WO 2005/051452	06-09-2005	Angiotech International AG		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
2F	59	Akselband, et al. "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts" Transplantation Proceedings, Vol. 23, No. 6. December 1991:p 2833-2836.	
	60	Auricchio, et al. "Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye" Molecular Therapy, July 1, 2002, p 238-242.	
	61	Bainbridge, et al. "Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization." Gene Therapy. 2003:p 1049-1054.	
	62	Humar, et al. " Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling." The FASEB Journal. Vol. 16. June 2002: p771-780.	
	63	Guba, et al. "Rapamycin inhibits tumor growth and metastasis by antiangiogenesis" Chirurgisches Forum 2001. May 1, 2001: p37-39.	
	64	Guba, et al. "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor." Nature Medicine. Vol. 8. No. 2. February 2002. p128-135.	
	65	Treins, et al. "Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway." Journal of Biological Chemistry, August 2, 2002. Vol. 277, No. 31 p. 27975-27981.	
	66	Kuroki, et al. "Rapamycin Inhibits Retinal and Choroidal Neovascularization in Mice." ARVO 2003 Abstract No. 573. May 4, 2003	
	67	Marsland. "The macrolide immunosuppressants in dermatology: mechanisms of action." Eur. J Dermatol. Nov-Dec 2002. p618-22.	
	68	Olsen, et al. "Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization," Arch. Ophthalmol, vol. 112, pp. 1471-1475, Nov. 1994	
2F	69	RENAU, et al., "Conformationally-Restricted Analogues of Efflux Pump Inhibitors that Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa." Bioorganic& Med. Chem. Letters. (2003) 13:2755-2758.	

Examiner Signature	<i>Zohreh Fay</i>	Date Considered	6/23/07
--------------------	-------------------	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/665,203
	Filing Date	September 18, 2003
	First Named Inventor	Rong Wen
	Art Unit	1618
(Multiple sheets used when necessary)	Examiner	Zohreh A. Fay
SHEET 4 OF 4	Attorney Docket No.	MACUS.002A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
Z-F	70	Renau, et al. "Addressing the Stability of C-Capped Dipeptide Efflux Pump Inhibitors that Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa." Bioorganic & Med. Chem. Letters. (2001) 11:663-667	
	71	"Study of possible anticancer drug reveals new mechanism of gene regulation." NewsRx. January 14, 2003	
	72	Shen, et al. "Combined Effect of Cyclosporine and Sirolimus on Improving the Longevity of Recombinant Adenovirus-Mediated Transgene Expression in the Retina." Arch Ophthalmol. July 2001. Vol. 119. p 1033-1043	
Zif	73	Wen, et al. "Rapamycin Inhibits Choroidal Neovascularization" ARVO 2003. Abstract No.3928 May 7, 2003.	

1903476:snd:sad2  
011806

Examiner Signature	<i>Zohreh Fay</i>	Date Considered	6/23/07
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.